The first 30 years of p53: growing ever more complex.

Levine, Arnold J., Oren, Moshe·2009·Nature Reviews Cancer
DOI 10.1038/nrc2723

Cited by (1,002)

Items 101–200 of 1,002

  1. Attractor Landscape Analysis Reveals Feedback Loops in the p53 Network That Control the Cellular Response to DNA Damage
    Minsoo Choi, Jue Shi, Sung Hoon Jung, Xi Xian Chen, Kwang‐Hyun Cho · 2012 · Science Signaling
  2. Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network
    Lilyn Daftuar, Yan Yu Zhu, Xavier Jacq, Carol L. Prives · 2013 · PLoS ONE
  3. Endoplasmic Reticulum Stress Induces G2 Cell-Cycle Arrest via mRNA Translation of the p53 Isoform p53/47
    Karima Bourougaa, Nadia Naski, Cédric Boularan, Coraline Mlynarczyk, Marco M. Candeias, Stéfano Marullo, Robin Fåhræus · 2010 · Molecular Cell
  4. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis
    Solmaz Shirjang, Behzad Mansoori, Samira Asghari, Pascal H. G. Duijf, Ali Mohammadi, Morten F. Gjerstorff, Behzad Baradaran · 2019 · Free Radical Biology and Medicine
  5. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
    Zhen Zhao, Johannes A. Zuber, Ernesto Díaz-Flores, Laura Lintault, Scott C. Kogan, Kevin Shannon, Scott W. Lowe · 2010 · Genes & Development
  6. Alternative splicing and cell survival: from tissue homeostasis to disease
    Maria Paola Paronetto, Ilaria Passacantilli, Claudio Sette · 2016 · Cell Death and Differentiation
  7. Perturbation of Ribosome Biogenesis Drives Cells into Senescence through 5S RNP-Mediated p53 Activation
    Kazuho Nishimura, Takuya Kumazawa, Takao Kuroda, Naohiro Katagiri, Mai Tsuchiya, Natsuka Goto, Ryohei Furumai, Akiko Murayama, Junn Yanagisawa, Keiji Kimura · 2015 · Cell Reports
  8. A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes
    Jing Song, Guannan He, Long Dai · 2023 · Biomedicine & Pharmacotherapy
  9. Caught in the cross fire: p53 in inflammation
    Tomer Cooks, Curtis C. Harris, Moshe Oren · 2014 · Carcinogenesis
  10. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
    Yan Stein, Varda Rotter, Ronit Aloni-Grinstein · 2019 · International Journal of Molecular Sciences
  11. A Novel p53/microRNA‐22/Cyr61 Axis in Synovial Cells Regulates Inflammation in Rheumatoid Arthritis
    Jinpiao Lin, Rongfen Huo, Lianbo Xiao, Xianjin Zhu, Jun Xie, Songtao Sun, Yong He, Jie Zhang, Yue Sun, Zhou Zhou et al. · 2013 · Arthritis & Rheumatology
  12. The transcription factor p53: Not a repressor, solely an activator.
    Fischer, Martin, Steiner, Lydia, Engeland, Kurt · 2014 · Cell Cycle
  13. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR)
    Maya Maor-Nof, Zohar Shipony, Rodrigo Lopez-Gonzalez, Lisa Nakayama, Yong‐Jie Zhang, Julien Couthouis, Jacob A. Blum, Patricia A. Castruita, Gabriel R. Linares, Kai Ruan et al. · 2021 · Cell
  14. Stearoyl CoA desaturase-1: New insights into a central regulator of cancer metabolism
    R. Ariel Igal · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  15. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
    Steven Pennock, Luis J. Haddock, Dean Eliott, Shizuo Mukai, Andrius Kazlauskas · 2014 · Progress in Retinal and Eye Research
  16. Current strategies to target p53 in cancer
    Fang Chen, Wenge Wang, Wafik S. El‐Deiry · 2010 · Biochemical Pharmacology
  17. p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis
    Christiane E. Olivero, Elena Martínez‐Terroba, Joshua T. Zimmer, Clara Liao, Ephrath Tesfaye, Nima Hooshdaran, Jeremy A. Schofield, Jordan Bendor, Dorthy Fang, Matthew D. Simon et al. · 2020 · Molecular Cell
  18. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis
    Slađana Bursać, Maja Cokarić Brdovčak, Giulio Donati, Siniša Volarević · 2013 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  19. Mechanisms of p53 degradation
    Chuck C.‐K. Chao · 2014 · Clinica Chimica Acta
  20. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention
    Alina Molchadsky, Noa Rivlin, Ran Brosh, Varda Rotter, Rachel Sarig · 2010 · Carcinogenesis
  21. Exploring the multiple roles of guardian of the genome: P53
    Wasim Feroz, Arwah Mohammad Ali Sheikh · 2020 · Egyptian Journal of Medical Human Genetics
  22. p53 Protein-mediated Regulation of Phosphoglycerate Dehydrogenase (PHGDH) Is Crucial for the Apoptotic Response upon Serine Starvation
    Yang Ou, Shang-Jui Wang, Le Jiang, Bin Zheng, Wei Gu · 2014 · Journal of Biological Chemistry
  23. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells
    Rachel Sarig, Noa Rivlin, Ran Brosh, Chamutal Bornstein, Iris Kamer, Osnat Ezra, Alina Molchadsky, Naomi Goldfinger, Ori Jacob Brenner, Varda Rotter · 2010 · The Journal of Experimental Medicine
  24. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism
    Ortmayr, Karin, Dubuis, Sébastien, Zampieri, Mattia · 2019 · Nature Communications
  25. Redox control in cancer development and progression
    Valeska Helfinger, Katrin Schröder · 2018 · Molecular Aspects of Medicine
  26. Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
    Subhasree Ashok Nag, X. Zhang, Kalkunte S. Srivenugopal, M.-H. Wang, W. Wang, Ruifeng Zhang · 2014 · Current Medicinal Chemistry
  27. The regulation of cellular metabolism by tumor suppressor p53
    Yingjian Liang, Juan Liu, Zhaohui Feng · 2013 · Cell & Bioscience
  28. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models
    Waleed Minzel, Avanthika Venkatachalam, Avner Fink, Eric Hung, Guy Brachya, Ido Burstain, Maya Shaham, Amitai Rivlin, Itay Omer, Adar Zinger et al. · 2018 · Cell
  29. p53 β-hydroxybutyrylation attenuates p53 activity
    Kun Liu, Fangzhou Li, Qianqian Sun, Ning Lin, Haichao Han, Kaiqiang You, Feng Tian, Zebin Mao, Tingting Li, Tanjun Tong et al. · 2019 · Cell Death and Disease
  30. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
    Lars‐Gunnar Larsson · 2011 · Seminars in Cancer Biology
  31. Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
    Hong Shen, Carl G. Maki · 2011 · Current Pharmaceutical Design
  32. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
    Flávia Alves Verza, Umashankar Das, Ana Lúcia Fachin, Jonathan Richard Dimmock, Mozart Marins · 2020 · Cancers
  33. ATM-Dependent Downregulation of USP7/HAUSP by PPM1G Activates p53 Response to DNA Damage
    Svetlana V. Khoronenkova, Irina I. Dianova, Nicola Ternette, Benedikt Mathias Kessler, Jason Luke Parsons, Grigory L. Dianov · 2012 · Molecular Cell
  34. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance
    Giorgia Acquaviva, Michela Visani, Andrea Repaci, Kerry Jane Rhoden, Dario de Biase, Annalisa Pession, Giovanni Tallini · 2017 · Histopathology
  35. Exploring the human diseasome: the human disease network
    K.-I. Goh, In‐Geol Choi · 2012 · Briefings in Functional Genomics
  36. DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions.
    Insinga, Alessandra, Cicalese, Angelo, Faretta, Mario, Gallo, Barbara, Albano, Luisa, Ronzoni, Simona, Furia, Laura, Viale, Andrea, Pelicci, Pier Giuseppe · 2013 · Proceedings of the National Academy of Sciences
  37. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
    Thorsten Stiewe, Tali E. Haran · 2018 · Drug Resistance Updates
  38. Update on Human Polyomaviruses and Cancer
    Ole V. Gjoerup, Yuan Chang · 2010 · Advances in cancer research
  39. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis
    Ju Liu, Congcong Zhang, X L Wang, Peter Ly, В. А. Белый, Zijun Yidan Xu-Monette, Ken H. Young, Wenwei Hu, Zhaohui Feng · 2014 · Cell Death and Differentiation
  40. LncRNAs: New Players in Apoptosis Control
    Marianna Nicoletta Rossi, Fabrizio Antonangeli · 2014 · International Journal of Cell Biology
  41. Interactions of Nucleolin and Ribosomal Protein L26 (RPL26) in Translational Control of Human p53 mRNA
    Jing Chen, Kexiao Guo, Michael B. Kastan · 2012 · Journal of Biological Chemistry
  42. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment
    Yan Ru Cui, Gang Guo · 2016 · International Journal of Molecular Sciences
  43. Gut bacterial isoamylamine promotes age-related cognitive dysfunction by promoting microglial cell death
    Yun Teng, Jingyao Mu, Fangyi Xu, Xiangcheng Zhang, Mukesh K. Sriwastva, Qiaohong M. Liu, Xiaohong Li, Chao Lei, Kumaran Sundaram, Xin Hu et al. · 2022 · Cell Host & Microbe
  44. Δ160p53 is a novel N‐terminal p53 isoform encoded by Δ133p53 transcript
    Virginie Marcel, Stéphane Perrier, Mustapha Aoubala, Sylvain Ageorges, Michael J. Groves, Alexandra Diot, Kenneth Fernandes, Sudhir Tauro, Jean‐Christophe Bourdon · 2010 · FEBS Letters
  45. Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons
    Houbo Jiang, Zhimin Xu, Ping Zhong, Yong Ren, Gaoyang Liang, Haley A. Schilling, Zihua Hu, Yi Zhang, Xiaomin Wang, Shengdi Chen et al. · 2015 · Nature Communications
  46. TP53mutations, expression and interaction networks in human cancers
    Xiaosheng Wang, Qingrong Sun · 2016 · Oncotarget
  47. Novel Evidence for Curcumin and Boswellic Acid–Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer
    Shusuke Toden, Yoshinaga Okugawa, Constanze Buhrmann, Durgha Nattamai, Esperanza Anguiano, Nicole E. Baldwin, Mehdi Shakibaei, Clement Richard Boland, Ajay Goel · 2015 · Cancer Prevention Research
  48. Tumor suppressor p53 and its gain-of-function mutants in cancer
    Juan Liu, Cen Zhang, Zhaohui Feng · 2013 · Acta Biochimica et Biophysica Sinica
  49. The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers
    Yan Pan, Chen Li, Jing Chen, Kai Zhang, Xiaoyuan Chu, Rui Wang, Longbang Chen · 2016 · Cellular Physiology and Biochemistry
  50. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
    Gluck, W. Larry, Gounder, Mrinal M., Frank, Richard, Eskens, Ferry, Blay, Jean Yves, Cassier, Philippe A., Soria, Jean-Charles, Chawla, Sant, de Weger, Vincent, Wagner, Andrew J. et al. · 2020 · Investigational New Drugs
  51. 5′-3′-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage
    Chen, Jing, Kastan, Michael B. · 2010 · Genes & Development
  52. Double-Edged Sword of Tumour Suppressor Genes in Schizophrenia
    Chuanjun Zhuo, Dawei Wang, Chunhua Zhou, Ce Chen, Jie Li, Hongjun Tian, Shen Li, Feng Ji, Chuanxin Liu, Min Chen et al. · 2019 · Frontiers in Molecular Neuroscience
  53. Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities
    Wamidh H. Talib, Asma Ismail Mahmod, Ayah Kamal, Hasan M. Rashid, Aya M. D. Alashqar, Samar H. Khater, Duaa Jamal, Mostafa I. Waly · 2021 · Current Issues in Molecular Biology
  54. Manumycin polyketides act as molecular glues between UBR7 and P53
    Isobe, Yosuke, Okumura, Mikiko, McGregor, Lynn M., Brittain, Scott M., Jones, Michael D., Liang, Xiaoyou, White, Ross, Forrester, William, McKenna, Jeffrey M., Tallarico, John A. et al. · 2020 · Nature Chemical Biology
  55. Identifying dysregulated pathways in cancers from pathway interaction networks
    Ke-Qin Liu, Zhi-Ping Liu, Jin‐Kao Hao, Luonan Chen, Xing‐Ming Zhao · 2012 · BMC Bioinformatics
  56. Discovery of Novel Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction
    Andreas Gollner, Dorothea Rudolph, Heribert Arnhof, Markus Bauer, Sophia M. Blake, Guido Boehmelt, Xiao-Ling Cockroft, Georg Dahmann, Peter Ettmayer, Thomas Gerstberger et al. · 2016 · Journal of Medicinal Chemistry
  57. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
    Sisi Chen, Qiang Wang, Hao Yu, Maegan L. Capitano, Sasidhar Vemula, Sarah C. Nabinger, Rui Gao, Chonghua Yao, Michihiro Kobayashi, Zhuangzhuang Geng et al. · 2019 · Nature Communications
  58. State of the art in medical applications using non-thermal atmospheric pressure plasma
    Hiromasa Tanaka, Kenji Ishikawa, Masaaki Mizuno, Shinya Toyokuni, Hiroaki Kajiyama, Fumitaka Kikkawa, Hans‐Robert Metelmann, Masaru Hori · 2017 · Reviews of Modern Plasma Physics
  59. Regulation of lipid metabolism by p53 – fighting two villains with one sword
    Ido Goldstein, Varda Rotter · 2012 · Trends in Endocrinology and Metabolism
  60. p53 and the Carcinogenicity of Chronic Inflammation
    Andrei V. Gudkov, Elena A. Komarova · 2016 · Cold Spring Harbor Perspectives in Medicine
  61. p53-dependent repression of polo-like kinase-1 (PLK1)
    Lynsey McKenzie, Sharon King, Lynnette Marcar, Sam Nicol, Sylvia S. Dias, Katie Schumm, Pamela Robertson, Jean‐Christophe Bourdon, Neil D. Perkins, Frances V. Fuller-Pace et al. · 2010 · Cell Cycle
  62. p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
    Shyhmin Huang, Sergi Benavente, Eric A. Armstrong, Chunrong Li, Deric L. Wheeler, Paul M. Harari · 2011 · Cancer Research
  63. Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression
    Ikuno Uehara, Nobuyuki Tanaka · 2018 · Cancers
  64. MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination
    Xinjiang Wang, Junru Wang, Xuejun Jiang · 2011 · Journal of Biological Chemistry
  65. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
    Huanan Wang, Lei Wang, Yingjie Zhang, Ji Wang, Yibin Deng, Degui Lin · 2016 · Cancer Cell International
  66. The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
    Anna Mandinova, Sam W. Lee · 2011 · Science Translational Medicine
  67. p53 can repress transcription of cell cycle genes through a p21<sup>WAF1/CIP1</sup>-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements
    Quaas, Marianne, Müller, Gerd A., Engeland, Kurt · 2012 · Cell Cycle
  68. Mdm2 and MdmX partner to regulate p53
    Xinjiang Wang, Xuejun Jiang · 2012 · FEBS Letters
  69. Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
    Kalliopi Tsafou, Purushottam Babu Tiwari, Julie Deborah Forman-Kay, Steven J. Metallo, Jeffrey A. Toretsky · 2018 · Journal of Molecular Biology
  70. Crosstalk between p53 and TGF- β Signalling
    Rebecca Elston, Gareth J. Inman · 2012 · Journal of Signal Transduction
  71. Profiling metabolic networks to study cancer metabolism
    Karsten Hiller, Christian M. Metallo · 2012 · Current Opinion in Biotechnology
  72. Tumor Suppressor p53 Alters Host Cell Metabolism to Limit Chlamydia trachomatis Infection
    Christine Siegl, Bhupesh Kumar Prusty, Karthika Rajeeve, Jörg Wischhusen, Thomas Rudel · 2014 · Cell Reports
  73. Cell Cycle–Targeted Cancer Therapies
    Charles J. Sherr, Jiří Bártek · 2016 · Annual Review of Cancer Biology
  74. Role of p63 in Development, Tumorigenesis and Cancer Progression
    Johann S. Bergholz, Zhi‐Xiong Jim Xiao · 2012 · Cancer Microenvironment
  75. p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage
    Lu Gong, Hongjian Gong, Xiao Pan, Changqing Chang, Zhao Ou, Shengfan Ye, Le Yin, Lina Yang, Ting Tao, Zhenhai Zhang et al. · 2015 · Cell Research
  76. Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-Gingerol in cervical cancer cells
    Namrata Rastogi, Shivali Duggal, Shailendra Kumar Singh, Konica Porwal, Vikas Kumar Srivastava, Rakesh Maurya, Madan Lal Brahma Bhatt, Durga Prasad Mishra · 2015 · Oncotarget
  77. Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC–p53 protein interactions
    Yuan Shen, Shanshan Liu, Jiao Jie Fan, Ying‐Hua Jin, Baolei Tian, Xiaofei Zheng, Hanjiang Fu · 2017 · EMBO Reports
  78. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression
    Paola Barboro, Nicoletta Ferrari, Cecilia Balbi · 2014 · Cancer Letters
  79. Integrating the DNA damage and protein stress responses during cancer development and treatment
    Gorgoulis, Vassilis G, Pefani, Dafni‐Eleftheria, Pateras, Ioannis S, Trougakos, Ioannis P · 2018 · The Journal of Pathology
  80. Bax, Bcl2, and p53 Differentially Regulate Neomycin- and Gentamicin-Induced Hair Cell Death in the Zebrafish Lateral Line
    Allison B. Coffin, Edwin W. Rubel, David W. Raible · 2013 · Journal of the Association for Research in Otolaryngology
  81. Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel
    Douglas Buckner Johnson, Kimberly H. Dahlman, Jared Knol, Jill Gilbert, Igor J. Puzanov, Julie Ann Means-Powell, Justin Micah Balko, Christine Marie Lovly, Barbara A. Murphy, Laura Williams Goff et al. · 2014 · The Oncologist
  82. Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53
    Hyeon‐Jun Shin, Hyuk‐Kwon Kwon, Jae-Hyeok Lee, Xiangai Gui, Asma Achek, Jae Ho Kim, Sangdun Choi · 2015 · Scientific Reports
  83. New plays in the p53 theater
    Aylon, Yael, Oren, Moshe · 2011 · Current Opinion in Genetics &amp; Development
  84. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer
    Satyanarayana Rachagani, Muzafar Ahmad Macha, Nicholas Heimann, Parthasarathy Seshacharyulu, Dhanya Haridas, Seema Chugh, Surinder K. Batra · 2014 · Advanced Drug Delivery Reviews
  85. Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop
    Xinyuan Zhang, Wenjing Wang, Hui Wang, M-H Wang, Wenrong Xu, R Zhang · 2012 · Oncogene
  86. The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction
    Che-Pei Kung, Julia I-Ju Leu, Subhasree Basu, Sakina Khaku, Frederick Anokye‐Danso, Qin Liu, Donna L. George, Rexford S. Ahima, Maureen E. Murphy · 2016 · Cell Reports
  87. Cooperation between p21 and Akt is required for p53‐dependent cellular senescence
    Young Yeon Kim, Hye Jin Jee, Jee‐Hyun Um, Young Mi Kim, Sun Sik Bae, Jeanho Yun · 2017 · Aging Cell
  88. Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.
    Nadine Darwiche · 2020 · PubMed Central
  89. Regulatory Roles for Long ncRNA and mRNA
    Armen Karapetyan, Coen Buiting, Renske A. Kuiper, Marcel W. Coolen · 2013 · Cancers
  90. Inhibition of AMP-activated Protein Kinase α (AMPKα) by Doxorubicin Accentuates Genotoxic Stress and Cell Death in Mouse Embryonic Fibroblasts and Cardiomyocytes
    Shaobin Wang, Ping Song, Ming‐Hui Zou · 2012 · Journal of Biological Chemistry
  91. The paradigm of mutant p53-expressing cancer stem cells and drug resistance
    Yoav Shetzer, Hilla Solomon, Gabriela Koifman, Alina Molchadsky, Stav Horesh, Varda Rotter · 2014 · Carcinogenesis
  92. SUMOylation of hnRNP‐K is required for p53‐mediated cell‐cycle arrest in response to DNA damage
    Seong Won Lee, Moon Hee Lee, Jong Ho Park, Sung Hwan Kang, Hee Min Yoo, Seung Hyeun Ka, Young Mi Oh, Young Joo Jeon, Chin Ha Chung · 2012 · The EMBO Journal
  93. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation
    Kaixuan Zeng, Xiaoxiang Chen, Xiuxiu Hu, Xiangxiang Liu, Tao Xu, Huiling Sun, Yuqin Pan, Bangshun He, Shukui Wang · 2018 · Oncogene
  94. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
    Harry Paul Erba, Pamela Sue Becker, Paul J. Shami, Michael Richard Grunwald, Donna Flesher, Min Zhu, Erik Rasmussen, Haby Adel Henary, Abraham Anderson, Eunice S. Wang · 2019 · Blood Advances
  95. p53, a novel regulator of lipid metabolism pathways
    Ido Goldstein, Osnat Ezra, Noa Rivlin, Alina Molchadsky, Shalom Madar, Naomi Goldfinger, Varda Rotter · 2011 · Journal of Hepatology
  96. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
    Heidi E. Greulich · 2010 · Genes & Cancer
  97. Interplay between Ribosomal Protein S27a and MDM2 Protein in p53 Activation in Response to Ribosomal Stress
    Xiao‐Xin Sun, Tiffany DeVine, Kishore B. Challagundla, Mu‐Shui Dai · 2011 · Journal of Biological Chemistry
  98. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
    Elena Tirrò, Federica Martorana, Chiara Romano, Silvia Rita Vitale, Gianmarco Motta, Sandra Di Gregorio, Michele Massimino, Maria Stella Pennisi, Stefania Stella, Adriana Puma et al. · 2019 · Genes
  99. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure
    Lu‐Nan Qi, Tao Bai, Zu-Shun Chen, Feixiang Wu, Yuan‐Yuan Chen, Bang De Xiang, Tao Peng, Ze‐Guang Han, Le‐Qun Li · 2014 · Liver International
  100. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase
    Chao Xu, Chuandong Fan, Xinjiang Wang · 2014 · Oncogene